Article
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Journal for immunotherapy of cancer - 1 Oct 2020
Hong Tae Hee, Cha Hongui, Shim Joon Ho, Lee Boram, Chung Jongsuk, Lee Chung, Kim Nayoung K D, Choi Yoon-La, Hwang Soohyun, Lee Yoomi, Park Sehhoon, Jung Hyun Ae, Kim Ji-Yeon, Park Yeon Hee, Sun Jong-Mu, Ahn Jin Seok, Ahn Myung-Ju, Park Keunchil, Lee Se-Hoon, Park Woong-Yang
Abstract excerpt
BACKGROUND: Tumor mutational burden (TMB) measurement is limited by low tumor purity of samples, which can influence prediction of the immunotherapy response, particularly when using whole-exome sequencing-based TMB (wTMB). This issue could be overcome by targeted panel sequencing-based TMB (pTMB) with higher depth of coverage, which remains unexplored. METHODS: We comprehensively reanalyzed four public datasets...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.